Related Experiment Videos
Cyclin-dependent kinase inhibitors: novel anticancer agents
1The Albert Einstein Cancer Center, Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Chanin 302, 1300 Morris Park Ave., Bronx, New York, 10461, USA.
Expert Opinion on Investigational Drugs
|November 4, 2000
Summary
Cyclin-dependent kinases (CDKs) control cell cycle progression. Inhibiting CDK activity is a promising strategy against cancer, with novel inhibitors like flavopiridol showing early clinical promise.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Cell cycle progression is regulated by checkpoints and driven by cyclin-dependent kinases (CDKs) complexed with cyclins.
- CDK activity is modulated by phosphorylation, dephosphorylation (by CDK-activating kinase and cdc25 phosphatases), and cyclin-dependent kinase inhibitors (CDKIs).
- Dysregulation of cell cycle control, including aberrant CDK/cyclin expression and loss of negative regulators like pRb, is a hallmark of cancer.
Purpose of the Study:
- To review recent advances in the field of cyclin-dependent kinase (CDK) inhibitors.
- To discuss the role of CDK inhibitors as a therapeutic strategy for malignant cellular proliferation.
Main Methods:
- Literature review of pertinent advances in CDK inhibitor research.
- Examination of the mechanisms of cell cycle regulation by CDKs, cyclins, and CDKIs.
- Discussion of clinical trial data for novel CDK inhibitors.
Main Results:
- Cellular neoplastic transformation is associated with loss of cell cycle checkpoint regulation.
- Inhibiting CDK activity or enhancing CDKI function represents a viable strategy to combat cancer.
- Novel CDK inhibitors, such as flavopiridol and UCN-01, are demonstrating early clinical tolerability.
Conclusions:
- Targeting CDKs offers a promising therapeutic avenue for cancer treatment.
- Continued research into CDK inhibitors is crucial for developing effective anti-cancer therapies.
- The development of novel CDK inhibitors shows potential for clinical application in oncology.